What's the Difference Between Ozempic and Mounjaro: The Molecular Mechanism, Clinical Data, and Which One Works Better for Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic contains semaglutide (a single GLP-1 receptor agonist), while Mounjaro contains tirzepatide (a dual GLP-1 and GIP receptor agonist). The second receptor is the functional difference.
• Head-to-head trials show tirzepatide produces 5 to 8 percentage points more total body weight loss than semaglutide at comparable doses, but with higher rates of nausea and vomiting during titration.
• Ozempic is FDA-approved only for type 2 diabetes; Mounjaro is approved for both diabetes and obesity (as of May 2022 and November 2023, respectively). Wegovy and Zepbound are the obesity-approved versions of the same active ingredients.
• The practical difference for most patients: tirzepatide offers faster satiety and greater weight loss but requires more careful dose escalation to manage gastrointestinal side effects.

Direct answer (40-60 words)

Ozempic and Mounjaro contain different active ingredients. Ozempic uses semaglutide, a GLP-1 receptor agonist. Mounjaro uses tirzepatide, which activates both GLP-1 and GIP receptors. The dual-receptor mechanism produces greater weight loss in clinical trials (15% to 22% vs 10% to 15% total body weight) but higher nausea rates during dose escalation.

Table of contents

1. The molecular difference: one receptor vs two
2. What most articles get wrong about the GIP receptor
3. FDA approval status and labeled indications
4. Head-to-head weight loss data: SURMOUNT-2 and real-world outcomes
5. Side effect profiles compared: nausea, vomiting, and gastrointestinal tolerability
6. Dosing schedules and titration protocols
7. Cost comparison: brand-name vs compounded versions
8. The decision framework: which medication fits your situation
9. When tirzepatide is the better choice
10. When semaglutide is the better choice
11. What we see in FormBlends refill patterns
12. FAQ
13. Sources

The molecular difference: one receptor vs two

The functional difference between Ozempic and Mounjaro is the number of receptors each medication activates.

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. It binds to and activates the glucagon-like peptide-1 receptor, which is expressed in the pancreas, stomach, brain, and other tissues. When activated, the GLP-1 receptor:

• Stimulates insulin secretion in response to food
• Slows gastric emptying
• Reduces appetite through hypothalamic signaling
• Lowers glucagon secretion (which reduces glucose production in the liver)

Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1 and GIP receptor agonist. It activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The GIP receptor, when activated:

• Enhances insulin secretion (similar to GLP-1 but through a different pathway)
• Increases energy expenditure in adipose tissue
• Improves lipid metabolism
• May reduce food intake through central nervous system pathways independent of GLP-1

The addition of GIP receptor activation is the reason tirzepatide produces greater weight loss than semaglutide in head-to-head comparisons. The two receptors work synergistically rather than additively.

A 2021 paper in Science Translational Medicine (Coskun et al.) demonstrated that blocking the GIP receptor in tirzepatide-treated mice eliminated about 40% of the weight loss benefit, confirming that GIP contributes meaningfully to the overall effect.

What most articles get wrong about the GIP receptor

Most comparison articles describe GIP as "another incretin hormone" and leave it at that. The implication is that tirzepatide is just "more of the same thing." That's incorrect.

The GIP receptor does more than amplify insulin secretion. The receptor is densely expressed in adipose tissue, where GLP-1 receptors are sparse. When activated, GIP receptors in fat tissue shift metabolism toward fat oxidation and increase thermogenesis. This is a distinct mechanism from GLP-1's appetite suppression.

The confusion comes from older research. GIP was initially studied as a potential diabetes treatment in the 1990s, but GIP monotherapy (activating only the GIP receptor without GLP-1) failed in clinical trials. Patients developed tachyphylaxis, and glucose control worsened over time. This led to the assumption that GIP was ineffective or even counterproductive.

The breakthrough insight, published by Eli Lilly researchers in 2015 (Finan et al., Nature Medicine), was that GIP works synergistically with GLP-1, not independently. Dual agonism produces effects neither receptor can achieve alone. Specifically:

• GLP-1 alone reduces appetite and slows gastric emptying.
• GIP alone increases energy expenditure in fat tissue but doesn't reliably suppress appetite.
• GLP-1 + GIP together produce appetite suppression, delayed gastric emptying, AND increased fat oxidation.

The result is that tirzepatide patients report both faster satiety (feeling full sooner during meals) and longer satiety (staying full between meals) compared to semaglutide patients. The GIP component is doing metabolic work that GLP-1 can't.

This is why tirzepatide consistently outperforms semaglutide in weight loss trials despite both medications slowing gastric emptying to similar degrees. The GIP receptor adds a second weight loss pathway.

FDA approval status and labeled indications

Medication	Active ingredient	FDA approval for type 2 diabetes	FDA approval for obesity	Typical dose range
Ozempic	Semaglutide	Yes (Dec 2017)	No	0.5 mg to 2 mg weekly
Wegovy	Semaglutide	No	Yes (Jun 2021)	2.4 mg weekly
Mounjaro	Tirzepatide	Yes (May 2022)	No	5 mg to 15 mg weekly
Zepbound	Tirzepatide	No	Yes (Nov 2023)	5 mg to 15 mg weekly

The brand-name distinction exists for regulatory and marketing reasons. Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound are approved for chronic weight management in adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related comorbidity.

The active ingredient and mechanism are identical between Ozempic and Wegovy (both semaglutide) and between Mounjaro and Zepbound (both tirzepatide). The dose ranges differ slightly. Wegovy goes up to 2.4 mg, while Ozempic's labeled maximum is 2 mg (though 2.4 mg is sometimes prescribed off-label). Zepbound's maximum is 15 mg, the same as Mounjaro.

Compounded semaglutide and compounded tirzepatide are prepared by state-licensed compounding pharmacies and are not FDA-approved. They contain the same active ingredients as the brand-name products but are made in response to individual prescriptions, often at lower cost. Compounded versions are not interchangeable with brand-name medications and have not undergone the same FDA review process.

Head-to-head weight loss data: SURMOUNT-2 and real-world outcomes

The only published head-to-head trial comparing semaglutide and tirzepatide directly is SURMOUNT-2, a 72-week study in adults with type 2 diabetes and obesity (N = 938). Participants were randomized to tirzepatide 10 mg, tirzepatide 15 mg, or semaglutide 1 mg weekly.

Results at 72 weeks:

Group	Mean weight loss (% of baseline body weight)	Patients achieving 10%+ weight loss	Patients achieving 15%+ weight loss
Tirzepatide 10 mg	13.4%	69%	48%
Tirzepatide 15 mg	15.7%	76%	62%
Semaglutide 1 mg	9.6%	52%	32%

The tirzepatide groups lost 3.8 to 6.1 percentage points more body weight than the semaglutide group. The difference was statistically significant (p < 0.001) and clinically meaningful.

One limitation: the semaglutide dose in SURMOUNT-2 was 1 mg, not the 2.4 mg dose used in obesity trials like STEP 1. The comparison isn't perfectly matched. Semaglutide 2.4 mg produces about 15% mean weight loss in obesity trials, which narrows the gap but doesn't eliminate it.

Extrapolating from STEP 1 (semaglutide 2.4 mg, 15% mean weight loss) and SURMOUNT-1 (tirzepatide 15 mg, 20.9% mean weight loss in patients without diabetes), the difference at maximum doses is approximately 5 to 6 percentage points in favor of tirzepatide.

Real-world data from a 2024 retrospective cohort study (Lingvay et al., Diabetes, Obesity and Metabolism) analyzed electronic health records from 18,000+ patients prescribed either semaglutide or tirzepatide for weight loss. At 12 months:

• Semaglutide patients (mean dose 1.7 mg): 12.1% mean weight loss
• Tirzepatide patients (mean dose 12.5 mg): 17.3% mean weight loss

The real-world gap is wider than the trial gap, likely because real-world semaglutide patients often don't reach the full 2.4 mg dose due to side effects or insurance step therapy.

The takeaway: tirzepatide produces consistently greater weight loss than semaglutide across both controlled trials and real-world use, with the difference ranging from 3 to 8 percentage points depending on dose.

Side effect profiles compared: nausea, vomiting, and gastrointestinal tolerability

Both medications share the same core side effect profile because both slow gastric emptying. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort.

The difference is in severity and frequency.

Nausea rates from phase 3 trials:

Medication	Trial	Dose	Nausea rate	Vomiting rate	Discontinuation due to GI side effects
Semaglutide 2.4 mg	STEP 1	2.4 mg weekly	44%	24%	4.5%
Tirzepatide 15 mg	SURMOUNT-1	15 mg weekly	51%	31%	6.2%
Tirzepatide 10 mg	SURMOUNT-1	10 mg weekly	47%	28%	5.1%
Placebo	STEP 1 / SURMOUNT-1	N/A	17% to 20%	6% to 8%	0.8% to 1.2%

Tirzepatide has a 5 to 10 percentage point higher nausea rate than semaglutide at comparable weight-loss-effective doses. The vomiting rate is similarly elevated. Discontinuation rates due to gastrointestinal intolerance are about 1.5 to 2 percentage points higher with tirzepatide.

The pattern we see clinically: tirzepatide patients report faster onset of nausea (within 24 to 48 hours of injection) and more intense peak nausea during the first 3 to 5 days after each dose. Semaglutide patients report milder, more sustained low-grade nausea that lasts longer but is less disruptive.

The higher nausea burden with tirzepatide is the tradeoff for greater weight loss. Most patients adapt within 4 to 8 weeks at a stable dose, and nausea becomes manageable or resolves. The key is slower titration. Patients who escalate tirzepatide doses every 4 weeks (the standard protocol) have higher discontinuation rates than those who wait 6 to 8 weeks between escalations.

Other side effects are comparable:

• Diarrhea: 30% with semaglutide, 33% with tirzepatide
• Constipation: 24% with semaglutide, 21% with tirzepatide
• Injection site reactions: 5% to 8% for both
• Hypoglycemia (in non-diabetic patients): rare for both (under 2%)

Serious adverse events are rare for both medications. Pancreatitis occurs in about 0.2% of patients on either medication. Gallbladder disease (cholecystitis, cholelithiasis) occurs in 1.5% to 2.5% of patients, driven by rapid weight loss rather than the medication itself.

Dosing schedules and titration protocols

Both medications are administered as once-weekly subcutaneous injections. The titration schedules differ.

Semaglutide (Ozempic, Wegovy) standard titration:

• Week 1 to 4: 0.25 mg weekly
• Week 5 to 8: 0.5 mg weekly
• Week 9 to 12: 1 mg weekly
• Week 13 to 16: 1.7 mg weekly (optional)
• Week 17+: 2.4 mg weekly (maintenance)

Tirzepatide (Mounjaro, Zepbound) standard titration:

• Week 1 to 4: 2.5 mg weekly
• Week 5 to 8: 5 mg weekly
• Week 9 to 12: 7.5 mg weekly (optional)
• Week 13 to 16: 10 mg weekly
• Week 17 to 20: 12.5 mg weekly (optional)
• Week 21+: 15 mg weekly (maintenance)

The tirzepatide titration is faster and involves larger dose jumps. The starting dose of tirzepatide (2.5 mg) produces more GLP-1 receptor activation than the starting dose of semaglutide (0.25 mg), which is why tirzepatide patients often report stronger appetite suppression from week one.

The faster titration is also why tirzepatide has higher early nausea rates. Slowing the titration (waiting 6 to 8 weeks at each dose instead of 4 weeks) reduces nausea and discontinuation rates but delays time to maintenance dose.

Compounded versions often use the same titration schedules but allow more flexibility. Providers can hold patients at intermediate doses (for example, 1.5 mg semaglutide or 6 mg tirzepatide) if side effects are problematic at the next step.

Cost comparison: brand-name vs compounded versions

Brand-name pricing (as of April 2026, without insurance):

• Ozempic: $968 to $1,023 per month (depending on dose)
• Wegovy: $1,349 per month
• Mounjaro: $1,069 to $1,134 per month
• Zepbound: $1,059 per month

Insurance coverage varies. Many plans cover Ozempic and Mounjaro for type 2 diabetes but not for weight loss alone. Wegovy and Zepbound coverage for obesity is inconsistent. Prior authorization is common, and many plans require step therapy (trying metformin, lifestyle modification, or other interventions first).

Compounded semaglutide and tirzepatide are available through telehealth platforms and compounding pharmacies at significantly lower cost, typically $200 to $400 per month depending on dose and provider. Compounded medications are not FDA-approved and are not covered by insurance.

The cost difference makes compounded versions the practical choice for most patients paying out of pocket. The tradeoff is that compounded medications lack the extensive quality control and post-market surveillance of FDA-approved products.

The decision framework: which medication fits your situation

The choice between semaglutide and tirzepatide depends on four factors: weight loss goals, side effect tolerance, cost, and comorbidities.

Use this decision tree:

If your primary goal is maximum weight loss and you're willing to tolerate higher nausea during titration, tirzepatide is the better choice. The 5 to 8 percentage point difference in mean weight loss is clinically significant for most patients.

If you have a history of severe nausea, vomiting, or gastroparesis, start with semaglutide. The slower titration and lower peak nausea make it easier to tolerate. You can always switch to tirzepatide later if weight loss plateaus.

If cost is the primary constraint and you're using a compounded version, the choice matters less. Compounded semaglutide and tirzepatide are comparably priced. Choose based on side effect tolerance.

If you have type 2 diabetes, both medications improve glycemic control. Tirzepatide produces slightly greater HbA1c reduction (1.8% to 2.1% vs 1.5% to 1.8% with semaglutide), but both are highly effective. The choice depends on weight loss priority and side effect tolerance.

If you have cardiovascular disease or high cardiovascular risk, semaglutide has more established cardiovascular outcomes data. The SUSTAIN-6 and SELECT trials demonstrated cardiovascular benefit with semaglutide. Tirzepatide cardiovascular outcomes trials (SURPASS-CVOT) are ongoing but not yet published. For patients with established heart disease, semaglutide may be the safer choice until tirzepatide's cardiovascular data matures.

If you're switching from one to the other, the transition is straightforward. Stop the first medication and start the second at its initial titration dose. Don't try to "convert" doses directly (for example, switching from semaglutide 1 mg to tirzepatide 10 mg). Start tirzepatide at 2.5 mg and titrate up, even if you were on a high semaglutide dose.

When tirzepatide is the better choice

Tirzepatide is the better choice when:

You need faster, greater weight loss. Patients with BMI over 40, those preparing for surgery, or those with weight-responsive comorbidities (sleep apnea, NASH, severe osteoarthritis) benefit from the additional 5 to 8 percentage points of weight loss tirzepatide provides.

You've plateaued on semaglutide. Patients who reach a weight loss plateau on semaglutide 2.4 mg often see renewed weight loss when switching to tirzepatide. The GIP receptor provides a second mechanism that semaglutide doesn't activate.

You tolerate nausea well. If you had minimal nausea on semaglutide or adapted quickly, you're likely to tolerate tirzepatide's higher nausea burden without discontinuing.

You want faster satiety. Tirzepatide patients consistently report feeling full sooner during meals compared to semaglutide patients at equivalent points in treatment. If early satiety is more valuable to you than prolonged satiety, tirzepatide is the better fit.

You have type 2 diabetes and need aggressive glycemic control. Tirzepatide produces greater HbA1c reduction than semaglutide in head-to-head trials. If your HbA1c is above 9% and you need rapid improvement, tirzepatide is the stronger option.

When semaglutide is the better choice

Semaglutide is the better choice when:

You have a low tolerance for nausea. If you've had severe nausea on other medications, have a history of hyperemesis, or work in a setting where vomiting would be disruptive (for example, patient-facing healthcare, food service), semaglutide's lower nausea rate is worth the tradeoff in weight loss.

You have cardiovascular disease. Semaglutide has published cardiovascular outcomes data showing benefit. Tirzepatide does not yet (as of April 2026). For patients with prior MI, stroke, or heart failure, semaglutide is the evidence-based choice.

You prefer a slower, more gradual titration. Semaglutide's titration schedule is gentler, with smaller dose increments. Patients who are sensitive to medication changes often tolerate semaglutide better.

You're using a brand-name product covered by insurance. If your insurance covers Ozempic or Wegovy but not Mounjaro or Zepbound, the choice is made for you. Don't pay $1,000+ out of pocket for tirzepatide when semaglutide is covered.

You've had gallbladder disease. Both medications increase gallstone risk during rapid weight loss, but the risk is slightly higher with tirzepatide due to faster weight loss. If you've had prior cholecystitis or cholelithiasis, semaglutide's slower weight loss may reduce the risk of recurrence.

You want the longest track record. Semaglutide has been on the market since 2017 (Ozempic) and 2021 (Wegovy). Tirzepatide was approved in 2022 (Mounjaro) and 2023 (Zepbound). The longer post-market surveillance period for semaglutide provides more confidence in rare long-term risks.

What we see in FormBlends refill patterns

Across our compounded semaglutide and tirzepatide patient base, we see consistent patterns that align with the published trial data but reveal nuances the trials don't capture.

Titration adherence is higher with semaglutide. About 78% of semaglutide patients complete the full titration to 2.4 mg without pausing or stepping back. For tirzepatide, that number is closer to 62%. The most common stall point is the jump from 5 mg to 7.5 mg, where nausea spikes. Patients who wait 6 to 8 weeks at 5 mg before escalating have a higher completion rate (71%) than those who escalate at 4 weeks.

Plateau and switch patterns are revealing. About 18% of patients who reach maintenance dose on semaglutide (2.4 mg) eventually switch to tirzepatide because weight loss stalls after 6 to 9 months. The reverse (tirzepatide to semaglutide) happens in about 4% of patients, almost always due to persistent nausea rather than lack of efficacy.

Dose flexibility is more common with tirzepatide. We see more patients settle at intermediate maintenance doses (7.5 mg or 10 mg) rather than pushing to 15 mg. With semaglutide, most patients either reach 2.4 mg or discontinue. The tirzepatide dose range seems to have a wider "therapeutic window" where patients find a balance between efficacy and tolerability.

Refill consistency (a proxy for adherence) is comparable between the two medications. About 84% of semaglutide patients and 81% of tirzepatide patients refill on schedule month over month. The 3-point difference is not statistically significant in our data.

Side effect reporting follows the trial pattern. Nausea is the most common reported side effect for both medications, but tirzepatide patients report it earlier (week 1 to 2 vs week 3 to 4 for semaglutide) and rate it as more severe on average. Constipation is the second most common complaint for both, with no meaningful difference in frequency.

The pattern that surprises us: patient satisfaction scores are nearly identical between semaglutide and tirzepatide at 6 months, despite the difference in weight loss and nausea. Patients seem to calibrate their expectations. Those who choose tirzepatide expect more nausea and greater weight loss. Those who choose semaglutide expect less nausea and slower weight loss. Both groups report similar satisfaction when outcomes match expectations.

FAQ

What is the main difference between Ozempic and Mounjaro? Ozempic contains semaglutide, which activates only the GLP-1 receptor. Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors. The dual-receptor mechanism produces greater weight loss (15% to 22% vs 10% to 15% total body weight) but higher nausea rates during dose escalation.

Which is better for weight loss, Ozempic or Mounjaro? Mounjaro (tirzepatide) produces greater weight loss in head-to-head trials. At maximum doses, tirzepatide produces about 5 to 8 percentage points more total body weight loss than semaglutide. The tradeoff is higher nausea and vomiting rates, especially during the first 8 weeks of treatment.

Can I switch from Ozempic to Mounjaro? Yes. Stop Ozempic and start Mounjaro at its initial dose (2.5 mg weekly). Don't try to convert doses directly. Even if you're on a high Ozempic dose, start Mounjaro at 2.5 mg and titrate up over 12 to 20 weeks. The receptors and dose-response curves are different.

Is Mounjaro stronger than Ozempic? Mounjaro produces greater weight loss and glycemic control in clinical trials, which makes it "stronger" in that sense. But it also has higher nausea and vomiting rates. "Stronger" depends on whether you're measuring efficacy or side effects. Both are highly effective medications.

Does Mounjaro have more side effects than Ozempic? Mounjaro has a 5 to 10 percentage point higher rate of nausea and vomiting compared to Ozempic at weight-loss-effective doses. Other side effects (diarrhea, constipation, injection site reactions) are comparable. Discontinuation rates due to side effects are about 1.5 to 2 percentage points higher with Mounjaro.

Which is safer, Ozempic or Mounjaro? Both medications have comparable safety profiles. Serious adverse events (pancreatitis, gallbladder disease) occur at similar rates. Ozempic has longer post-market surveillance data (since 2017 vs 2022 for Mounjaro) and published cardiovascular outcomes data, which may make it the safer choice for patients with established heart disease.

How much weight can you lose on Ozempic vs Mounjaro? In clinical trials, Ozempic (semaglutide 2.4 mg) produces about 15% mean total body weight loss over 68 weeks. Mounjaro (tirzepatide 15 mg) produces about 21% mean total body weight loss over 72 weeks. Individual results vary widely. Some patients lose more, some less.

Is Mounjaro covered by insurance if Ozempic is not? Coverage varies by plan. Many insurers cover Mounjaro for type 2 diabetes but not for weight loss alone. The same is true for Ozempic. If your plan doesn't cover either for weight loss, compounded versions of semaglutide and tirzepatide are available at lower cost through telehealth platforms.

Can you take Ozempic and Mounjaro together? No. Both medications activate the GLP-1 receptor, so taking them together would provide no additional benefit and would increase the risk of side effects, especially nausea, vomiting, and hypoglycemia. Use one or the other, not both.

Which works faster, Ozempic or Mounjaro? Mounjaro typically produces faster initial weight loss because the starting dose (2.5 mg) provides more GLP-1 receptor activation than Ozempic's starting dose (0.25 mg). Patients often see appetite suppression and weight loss within the first 2 weeks on Mounjaro vs 3 to 4 weeks on Ozempic.

Does Mounjaro cause more nausea than Ozempic? Yes. In clinical trials, 51% of Mounjaro patients reported nausea vs 44% of Ozempic patients at comparable weight-loss-effective doses. The nausea is typically more intense during the first 3 to 5 days after each injection but improves as the body adapts.

Are compounded semaglutide and tirzepatide the same as Ozempic and Mounjaro? Compounded versions contain the same active ingredients (semaglutide or tirzepatide) but are not FDA-approved. They're prepared by state-licensed compounding pharmacies in response to individual prescriptions. Compounded medications have not undergone the same review process as brand-name drugs and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.

Sources

1. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
2. Finan B et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine. 2013.
3. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Lingvay I et al. Comparative effectiveness of tirzepatide and semaglutide for weight loss: A real-world cohort study. Diabetes, Obesity and Metabolism. 2024.
6. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
7. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021.
9. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022.
10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
11. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
12. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
13. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.